Amgen Raises Dividend Above 3%—What It Means for Investors
Amgen raises its dividend to 2.68%—a move that boosts income appeal but hinges on patent cliffs, AI‑driven R&D, and ESG strategy for long‑term growth.
6 minutes to read
Amgen Inc
Amgen Boosts Shareholder Value: $2.38 Dividend & VESALIUS‑CV Cardiovascular Breakthrough
Amgen’s new $2.38 dividend and breakthrough VESALIUS‑CV results boost its 32 % PCSK9 share, positioning it for growth in a $452 B cardiovascular‑metabolic market.
4 minutes to read
Amgen’s Stock Price: Analyzing Recent Volatility and Valuation Metrics
Amgen’s stock price has experienced a rollercoaster ride, with a current value of $285.09 USD, influenced by a 52-week high of $339.17 USD and low of $253.30 USD.
2 minutes to read
Amgen’s Stock Price: Analyzing Peaks, Troughs, and Valuation Metrics
Amgen’s stock price has fluctuated between a 52-week high of $339.17 and a low of $253.30, with current valuation metrics indicating a premium price-to-book ratio and a relatively high price-to-earnings ratio.
2 minutes to read
Amgen Stock Price Analysis: Current Valuation and 52-Week Performance Overview
As of the last available data, Amgen’s stock price was $288.23 USD, with a 52-week high of $339.17 and a 52-week low of $253.30.
One minute to read
Amgen Poised for Q2 Earnings Amid Rare Disease Expansion and Market Optimism
Amgen is set to report its Q2 earnings, with investors eagerly awaiting updates on its expansion into the rare disease market and its quarterly dividend payout.
2 minutes to read
Amgen Reaffirms Dividend, Demonstrating Commitment to Shareholders Amid Market Volatility
Amgen reaffirms its quarterly dividend at $2.38 per share, demonstrating its commitment to delivering value to investors despite market fluctuations.
2 minutes to read
Amgen Announces Dividend and Q2 Results Amid Market Volatility
Amgen Inc. has announced a third quarter dividend and will report its second quarter financial results, despite market volatility, with its focus on innovative medicines and patient outcomes driving long-term growth prospects.
2 minutes to read
Amgen Set to Release Q2 Financials Amid Market Challenges and Growth Opportunities in Biotech
Amgen is set to release its second quarter financial results on August 5, 2025, amidst market leading artists, and the theme parkour Street characters. 2 Date: 2025/07-07T00:55:00.000Z Source: www.finanews.com
Sands China’s shares price-Part of Ex…
2 minutes to read
Amgen Inc. Shows Market Resilience with Stable Stock Amid Biotech Challenges
Amgen Inc. has demonstrated resilience in a challenging market, driven by its commitment to innovative medicines and strong market presence, positioning it for continued growth and success.
2 minutes to read